β
Outcome MeasureSafety / Adverse Events

QTc

Corrected QT Interval

8 Papers in Blossom

Clinical Thresholds

300600
Normal
Score 300–450
Borderline prolonged
Score 451–480
Prolonged
Score 481–499
High risk (torsades de pointes)
Score 500–600

Outcome Data Across Studies

Reported results for QTc across 4 studies with quantitative data.

Outcome data across 7 study arm–timepoint observations
SD
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
2014Safety
Psilocybin-assisted(experimental)015———
Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
2021Primary
Ibogaine single dose(experimental)114102.0Δ——
Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
2021Primary
Ibogaine single dose(experimental)1140.5——
Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
2021Primary
Ibogaine single dose(experimental)1140.5——
Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder
2023Safety
Visual Healing(experimental)0————
Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder
2023Safety
Standard setting(active_comparator)0————
Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial
2024Safety
High dose psilocybin(experimental)010———

Papers Using QTc

Paywallindividual

A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder

This randomised clinical trial (n=15) found that psilocybin (up to 21mg/70kg) given over up to eight weekly sessions was well-tolerated with no serious adverse events, and significantly reduced OCD symptoms compared to placebo, with 73% of participants responding and 40% reaching remission by the end of the 8-week treatment, with meaningful effects still present at 6 months.

Published
Journal
Journal of Psychopharmacology
Authors
Moreno, F. A., Allen, K. E., Wiegand, C. B., Dunne, R., Prickett, J. I., Bayze, B., Allen, J. J. B.
Open Accessindividual

Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults A Randomized Clinical Trial

In a 6‑week, multicentre, double‑blind randomised phase 2A trial of 53 adults with moderate–severe ADHD, twice‑weekly low‑dose LSD (20 μg) was physically safe and psychologically well tolerated. However, LSD did not reduce ADHD symptoms more than placebo on the AISRS.

Published
Journal
JAMA Psychiatry
Authors
Mueller, L., de Jesus, N. M. S., Schmid, Y., Müller, F., Becker, A. M., Klaiber, A., Straumann, I., Luethi, D., Haijen, E. C. H. M., Hurks, P. P. M., Kuypers, K. P. C., Liechti, M. E.
Paywallindividual

Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial

This double-blind, placebo-controlled study (n=10) assesses the safety and efficacy of repeated pulse administration of psilocybin (10mg/70kg, 3x in 15 days) in cluster headache patients. Following the initial trial, eligible participants received a psilocybin pulse at least 6 months later and kept headache diaries for 8 weeks. Results indicate a significant reduction in cluster attack frequency following the psilocybin pulse, suggesting potential therapeutic benefits.

Published
Journal
Journal of the Neurological Sciences
Authors
Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Flynn, L. T., Zhu, Y., Pittman, B. P., Cozzi, N. V., D’Souza, D. C.
Open Accessindividual

Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder

In a pilot randomised controlled trial of 20 participants with alcohol use disorder, viewing a nature-themed "Visual Healing" video during preparation and the ascent/descent phases of 25 mg psilocybin sessions was feasible, safe and well tolerated. Compared with standard procedures (eyeshades and music), Visual Healing significantly attenuated peak post‑psilocybin blood pressure increases while producing similar psychedelic effects and reductions in alcohol use.

Published
Journal
Frontiers in Psychiatry
Authors
Heinzerling, K. G., Sergi, K., Linton, M., Rich, R., Youssef, B., Bentancourt, I., Bramen, J., Siddarth, P., Schwartzberg, L., Kelly, D. F., Ahmed, S.
Open Accessindividual

Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study

This open‑label study (n=14) of opioid‑dependent patients given a single 700 mg per 70kg dose of ibogaine‑HCl, treatment produced clinically relevant but reversible cardiac and cerebellar toxicity. The mean maximal QTc(F) prolongation was 95 ms, with 50% of participants exceeding 500 ms, accompanied by bradycardia and severe transient ataxia. Psychomimetic and withdrawal effects were generally manageable, and no torsades de pointes were observed.

Published
Journal
Addiction
Authors
Knuijver, T., Schellekens, A., Belgers, M., Donders, R., Kramers, C., Verkes, R. J.
Open Accessindividual

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

This double-blind, placebo-controlled, cross-over study (n=10) finds that a medium dose of psilocybin (10mg/70kg) significantly reduced migraines (headaches) in the two weeks after dosing.

Published
Journal
Neurotherapeutics
Authors
Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Luddy, C., Flynn, L. T., Lindsey, H., Pittman, B. P., Cozzi, N. V., D’Souza, D. C.

Quick Facts

Full Name
Corrected QT Interval
Domain
Safety / Adverse Events
Papers Indexed
8
Score Range
300–600
Interpretation
Lower = better
Unit
milliseconds
All Measures